Renaissance Technologies LLC Purchases 31,435 Shares of Phibro Animal Health Corporation $PAHC

Renaissance Technologies LLC raised its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 576,735 shares of the company’s stock after buying an additional 31,435 shares during the quarter. Renaissance Technologies LLC’s holdings in Phibro Animal Health were worth $31,899,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Sei Investments Co. grew its position in shares of Phibro Animal Health by 15.7% in the 1st quarter. Sei Investments Co. now owns 156,948 shares of the company’s stock worth $8,681,000 after buying an additional 21,339 shares during the period. Cetera Investment Advisers increased its stake in shares of Phibro Animal Health by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after acquiring an additional 293 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Phibro Animal Health by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company’s stock valued at $28,086,000 after acquiring an additional 15,517 shares during the period. KBC Group NV purchased a new position in Phibro Animal Health during the 1st quarter valued at about $29,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Phibro Animal Health by 145.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock worth $15,671,000 after acquiring an additional 169,628 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Insider Activity

In other news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the transaction, the chief executive officer owned 67,720 shares in the company, valued at approximately $3,778,776. This represents a 9.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,608 shares of company stock valued at $983,825 in the last 90 days. Corporate insiders own 50.13% of the company’s stock.

Analysts Set New Price Targets

PAHC has been the topic of a number of recent research reports. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup dropped their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Finally, Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $42.50.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $36.37 on Wednesday. The business has a fifty day moving average price of $32.52 and a 200-day moving average price of $43.24. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The company has a market capitalization of $1.48 billion, a PE ratio of 15.61, a PEG ratio of 0.49 and a beta of 0.46. Phibro Animal Health Corporation has a 1-year low of $25.58 and a 1-year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The company had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities analysts expect that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a yield of 1.3%. Phibro Animal Health’s payout ratio is 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.